User profiles for John JV McMurray
John McMurrayUniversity of Glasgow. Verified email at glasgow.ac.uk Cited by 488335 |
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart …
…, JJV McMurray… - European heart …, 2012 - academic.oup.com
The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …
research, but also the creation of educational tools and implementation programmes for the …
[HTML][HTML] Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi… - … England Journal of …, 2019 - Mass Medical Soc
Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2)
reduce the risk of a first hospitalization for heart failure, possibly through glucose-…
reduce the risk of a first hospitalization for heart failure, possibly through glucose-…
[HTML][HTML] Eplerenone in patients with systolic heart failure and mild symptoms
F Zannad, JJV McMurray, H Krum… - … England Journal of …, 2011 - Mass Medical Soc
Background Mineralocorticoid antagonists improve survival among patients with chronic,
severe systolic heart failure and heart failure after myocardial infarction. We evaluated the …
severe systolic heart failure and heart failure after myocardial infarction. We evaluated the …
[HTML][HTML] Angiotensin–neprilysin inhibition versus enalapril in heart failure
Background We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with
enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, …
enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, …
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM …
Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic
measurements, neurohumoral activity, and left-ventricular remodelling when added to …
measurements, neurohumoral activity, and left-ventricular remodelling when added to …
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart …
…, G Filippatos, JJV McMurray… - European heart …, 2008 - academic.oup.com
ESC Guidelines 2389 disclosure forms are kept on file at the European Heart House,
headquarters of the ESC. Any changes in conflict of interest that arise during the writing period …
headquarters of the ESC. Any changes in conflict of interest that arise during the writing period …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
…, CSP Lam, AR Lyon, JJV McMurray… - European journal of …, 2022 - Wiley Online Library
Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator) (Netherlands), P.
Christian Schulze (CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor …
Christian Schulze (CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor …
[HTML][HTML] Apixaban versus warfarin in patients with atrial fibrillation
CB Granger, JH Alexander, JJV McMurray… - … England Journal of …, 2011 - Mass Medical Soc
Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor …
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
…, CSP Lam, AR Lyon, JJV McMurray… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
[HTML][HTML] Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure and cardiovascular death among patients with chronic heart failure …
for heart failure and cardiovascular death among patients with chronic heart failure …